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INTRODUCTION
Diabetes mellitus is a disease whose incidence is increasing
worldwide and gaining epidemic proportions. Among all its
complications, cardiovascular disease is in majority, the frequent reason
for mortality (1).
Over the last 30 yrs, numerous statistical, clinical and post-mortem
studies have identified diabetic cardiac disease to be a separate clinical
variable. (2-5).  Numerous  studies have shown diabetes can affect the
structure as well as functions of  the heart even without conventional
threat factors such as coronary artery disease and hypertension.
Diabetic cardiomyopathy has been advocated as an independent
cardiovascular disease and multiple mechanisms such as microvascular
pathology, autonomic dysfunction, disorders in metabolic pathways and
interstitial fibrosis have been proposed as causative factors (6).
However, the accurate aetiopathogenesis of diabetic
cardiomyopathy is not clear. New studies prove that diseases involving
both the microvasculature and macrovasculature are associated with
coronary events.
Diabetic cardiomyopathy is characterised by defects in functions of
both systole and diastole (7). Diabetic heart disease’s spectrum progresses
from being normal to preclinical dysfunction of diastole and systole,
leading to overt echocardiographic indices of evident LV dysfunction and
ultimately fully blown heart failure with symptoms. In patients sans overt
disease at beginning, the occurrence of subclinical ailment has association
with  augmented  risk  of  cardiac  disease,(8)  with  the  amplified   risk  of
overall  death  as  3  for  men  and  1.7  in  women  (9).  Apart  from  the
mortality, there is impairment of functional capacity as well.
After the onset of full blown heart failure signs and symptoms the
prognostic prospects are generally worse (10-13). Hence, measures to
identify risk variables contributing to this burdensome cardiac failure in
subjects of diabetes mellitus are crucial in decreasing the associated
moribund status.
Current statistics from the study of Atherosclerosis Risk in
Communities (ARIC) has exhibited a connection involving retinopathy,
and heart failure development (14). The former is a microvascular disease
indicator and the latter is traditionally viewed as a macrovascular disease.
With more worsening of retinopathy severity, the mass of left ventricles
increased, so also that of atrium and the systolic fraction decreased. These
findings were found independent of influential confounding variables.
Another study namely the Multi-Ethnic Study of Atherosclerossis
(MESA) also established that retinopathy was coupled with accelerated
remodeling of cardiac structures as evidenced by MRI of the heart in
diabetic patients (15).
Thus  the  studies  lead  to  a  possible  suggestion  that  there  exists  a
probable microvascular involvement in the concurrence of cardiac
dysfunction coupled with diabetes or a potential link between
microvascular retinopathy and the so called macrovascular heart disease
due to common pathophysiological pathways of both disorders (16-18).
In an era where both diabetes and heart failure contribute to the
overall burden of the medical system, it is prudent to identify
abnormalities contributing to the linked association between heart failure
and retinopathy. At least, we should trigger evaluation of retinopathy in
type 2 diabetes patients for further cardiac status. And further treatments
targeted at the microvascular disease may ultimately decrease
macrovascular disease risk as well and that might be greatly beneficial in
the vast diabetic population.
REVIEW OF LITERATURE
HISTORY
Diabetes mellitus is one of the foremost diseases to be
described, with an Egyptian manuscript as early as 1500 B.C. where it is
mentioned as TOO GREAT EMPTYING OF THE URINE.
The first complete clinical description of diabetes was given by a
physician of Greece by name Aretaeus from Cappadocia. He also coined
the name “diabetes.”  Thomas Willis of England in 1675 later added the
word mellitus meaning honey/sweet.
Indian physicians Sushruta and Charaka identified separately types
1 and 2 diabetes in 400-500 AD. Sir Harold Percivial Himsworth clearly
made the distinction in 1936.
The role of the liver in glycogenesis was established by French
physician Claude Bernard in 1857.
The contribution of pancreas in causing diabetes was identified by
Mering and Minkowski belonging to Austria.
An important milestone was the discovery of insulin by Canadians
- Banting and Best in 1921. Oral Hypoglycemic Agents were
subsequently discovered and marketed in 1955.
BANTING AND BEST
CLASSIFICATION ACCORDING TO ETIOLOGY:
1) Type 1 DM
     A. Immune-regulated
     B. Idiopathic
2) Type 2 DM
3)   Additional definite forms
      A. Genetic problems of function of beta cells due to mutations:
1. Maturity Onset Diabetes in Young - MODY 6 types
2. Mitochondrial DNA
3. Involving ATP K+ channel
4. Insulin/Proinsulin
B. Genetic derangements in action of insulin
1. Insulin resistance-Type A
2. Leprechaunism
3. Lipodystrophy
     C. Pancreas – exocrine part diseases
D. Endocrinopathies
     E. Drug- or chemical-induced
     F. Viral Infections
     G. Rare forms of immune-regulated diabetes
     H. Genetic syndromes
4) Gestational DM
SPECTRUM OF DIABETES
NORMAL
GLUCOSE
TOLERANCE
PRE-DIABETES
(IMPAIRED FASTING
GLUCOSE OR
IMPAIRED GLUCOSE
TOLERANCE)
DIABETES
MELLITUS
DIAGNOSTIC CRITERIA:
As  proposed by the AMERICAN DIABETES ASSOCIATION
2011,a diagnosis of DM is made by presence of either of the following:
? Diabetic symptoms + a random blood glucose of 200 mg/dl.
? Plasma glucose  in fasting state of 126 mg/dl.
? 2 hr post prandial plasma glucose of 200 mg/dl.
? HbA1C >6.5%
 RISK ATTRIBUTES
Family history
Obesity
Lack of activity
Specific ethnicity
History of GDM
High blood pressure
Low HDL cholesterol level or high triglycerides
PCOS or Acanthosis nigricans
Post cardiac disease
COMPLICATIONS
ACUTE COMPLICATIONS
The acute complications are ketoacidosis and nonketotic
hyperglycemic hyperosmolar coma. Though the latter is seen
predominantly in type 2 DM, DKA is no more considered pathognomonic
of type 1 DM as it can occur with either types. The characteristics are
depletion of volume, abnormalities of acid-base and absolute or relative
deficiencies of insulin with or without ketosis.
CHRONIC COMPLICATIONS
It affects multiple organ systems contributing to majority of
morbidity and mortality.
VASCULAR
MICROVASCULAR MACROVASCULAR
Retinopathy
Cardiovascular system
disease
Neuropathy
Peripheral vascular
disease
Nephropathy Stroke
NON-VASCULAR
Altered bowel habits
Urogenital problems
Skin diseases
Susceptibility to infections
Eye - glaucoma, cataracts
Periodontal disease
Loss of Hearing
The  risk  of  incurring  the  above  complications  amplifies  with  the
time duration and severity. But since the type 2 disease has a lengthy
symptomless period, many patients present with complications even
initially during diagnosis.
COMPLICATIONS INVOLVING THE MICROVASCULATURE:
RETINOPATHY
It is among the foremost microvascular complications in DM. It is
characterized by typical lesions involving the microvasculature of the
retina such as microaneurysms, haemorrhages and exudates. The others
are venous changes, neovascularisation and thickening of the retina.
Ultimately if left untreated, it might lead to loss of vision.
NEPHROPATHY
It is a severe complication which has the hallmark features of
thickened basement membranes, glomerular hyperfiltration, expansion of
mesangium and matrix, formation of Kimmelsteil-Wilson nodules and
glomerular and tubular sclerosis .The earliest manifestation is
microalbuminuria, which progresses to frank albuminuria and eventually
to renal failure and end-stage renal disease (ESRD) (19-22).
DIABETIC NEUROPATHY
Peripheral neuropathy manifests as various forms such as sensory,
motor-focal/multifocal and autonomic neuropathies. The most common
form is chronic sensorimotor distal symmetric polyneuropathy. Pure
sensory neuropathy is quite rare. Mononeuropathies occur with the nerves
of the upper limb-median nerve, ulnar or the radial nerve or even the
cranial nerves.
Diabetic amyotrophy is a condition where there is pain, weakness
of muscles and hypotrophy involving the muscles of thigh. All these may
ultimately lead to foot injury, ulceration and, amputations. Autonomic
neuropathy manifests by gastroparesis, constipation, diarrhoea, sexual
and bladder dysfunction, intolerance of exercise, tachycardia at rest and
sudden cardiac death.
MACROVASCULAR COMPLICATIONS:
CARDIAC DISEASE
It is the chief cause of mortality in diabetic people who have 4.5
times increased danger for cardiac disease even after adjusting for
conventional risk attributes such as high BMI, altered lipid profile and
high BP. These attributes combined with the sole independent attribute of
diabetes per se notably augment risk for cardiovascular disease.
CEREBROVASCULAR DISEASE
Diabetes mellitus is an autonomous risk variable in every age
group for cerebrovascular disease; so also for severe neurological deficits
and the following disability and also for sudden death. Risk factors are
hyperglycemia, atrial fibrillation and also the microvascular
complications.
PERIPHERAL VASCULAR DISEASE
It is manifested by arterial occlusion of legs, leading to
claudication and pain intermittently and chiefly upon stress.
Hyperglycemia, obesity, high serum fibrinogen levels and physical
inactivity contribute to it. The central pathogenesis is atherosclerosis.
Other contributors are increased tendencies for platelet adhesion,
aggregation, therefore hypercoagulable state and impaired fibrinolysis
(28-32).
CURRENT LITERATURE OF THIS STUDY
The recognition of a cardiomyopathy in diabetics was primarily
projected by Rubler et al on the background of autopsy results (33). Both
systolic and diastolic function abnormalities have been established in
studies done in humans as well as in animals (34-37). The etiology of this
type of LV dysfunction is not totally known (38).
Studies done in DM without CAD have verified that in people with
various grades of retinopathy, dysfunction in diastole was present
compared to people without retinopathy (39, 40). In a study by Annonu et
al, a greater frequency of retinopathy was noted in subjects with atypical
LV filling compared to the standards with normal diastole (41).
Nevertheless, this link was not persistently found. In the analysis
by Airaksinen et al (42) and Uusitupa et al(43) , retinopathic patients  did
not diverge from the other subjects.
DIABETIC RETINOPATHY
INTRODUCTION
A major microvascular complication of diabetes is diabetic
retinopathy.  It occurs in both the types and it has been observed that
virtually all type 1 and 76 % of DM will go on to retinopathy after 15 yrs
(44).  In  our  country  with  the  drastic  surge  in  type  2  DM,  diabetic
retinopathy has become a chief cause of visual disability (45).
Nevertheless, this is hugely avertable and manageable with timely
intervention.
RISK FACTORS
Apart from the ocular factors like detachment of the vitreous, surgeries
for cataract and chorioretinopathies, various systemic factors also play a
role in the pathogenesis of diabetic retinopathy.
SYSTEMIC FACTORS
 Gender
Diabetic duration
Control of glycemic status
High BP
Renal disease
Dyslipidemia
Alcohol
Anemia
Obesity
SEX: Various analyses have failed to show stable outcomes in evaluating
gender as a risk variable in retinopathy.
DISEASE DURATION: The time duration of diabetes disease is
perhaps the most important risk variable for developing retinopathy. This
goes  with  the  studies  of  WESDR  (44),  Dandona  et  al  (46)  and  CURES
Eye study (47) .Furthermore it has also been studied that for each 5 year
increase in span of disease, retinopathy risk is amplified by 2 .
CONTROL OF GLYCAEMIC STATUS: This fact that glycemic
levels reflect on retinopathy is supported by studies like WESDR, DCCT
and UKPDS (44, 48, 49).
HYPERTENSION:  Studies have proven association betweeen high BP
and the concurrence and severity of retinopathy in diabetic population
(49, 50).
RENAL DISEASE: The links between angiopathy in renal and retinal
systems  in  diabetes  have  been  studied  (51,  52).  These  may  possibly  be
mediated through hypertension, high levels of fibrinogen and altered
lipoproteins.
DYSLIPIDEMIA: This may contribute in the form of increased total
serum cholesterol, elevated fractions of low-density form or triglycerides
(44, 53).
ALCOHOL: Young et al and The Casteldaccia Eye Study (54, 55) have
linked alcohol and retinopathy with respect to quantity and duration of
alcohol. But this is disproved in WESDR (44).
OBESITY: BMI had a noteworthy value in retinopathy as evidenced by
CURES (47), Zhang et al.(56)
OTHER FACTORS
? increased oxidative stress (57)
? Growth factors such as VEGF,GH and TGF- ?
? intima-media thickness  and arterial stiffness
? decreased glutathione levels
? genetic factors
MOLECULAR PATHOGENESIS OF RETINOPATHY
The range of changes that could occur in the retina are:
(i) Development of capillary microaneurysms
(ii) Undue vascular permeability
 (iii) Vascular occlusion
 (iv) Angiogenesis and new fibrous tissue formation.
(v) The tightening of the above fibrovascular proliferations (58).
Four   key biochemical pathways are in proposal (59). They are:
 (i) Improved glucose flux via the polyol gateway.
 (ii) Augmented production of advanced glycation end-products
(iii) Protein kinase C activation.
(iv)  Activation of hexosamine gateway.
GRADING
1) BACKGROUND (NON-PROLIFERATIVE) DIABETIC
RETINOPATHY:
It is defined by occurrence of microaneurysms, intraretinal
hemorrhages which could be punctuate or striate and exudates,
particularly hard exudates. Microaneurysms are tiny vascular
outpouchings occuring as the earliest finding. They seem as red dots on
visualisation of the retina.
Haemorrhages are classically of the dot type. Hard exudates are
formed due to accumulation of lipid over the edges of hemorrhages.
Edema of the retina may be due to microvascular leakage as a result of
breach of blood retina barrier.
Fig-1. Background diabetic retinopathy
2) PREPROLIFERATIVE type is described by exudates (soft),
venous beading, and intraretinal microvascular abnormalities.
Fig- 2. Preproliferative diabetic retinopathy
3) PROLIFERATIVE DIABETIC RETINOPATHY depicted by
neovascularization  on  disc  or  contained  by  one  disc  diameter  from  the
disc.  The  former  is  known  as  new  vessels  on  the  disc  (NVD)  and  the
latter is known as new vessels elsewhere (NVE).
Fig -3. Proliferative diabetic retinopathy with NVD.
Fig-4. Proliferative type with haemorrhages in vitreous and pre-retinal
zone.
Fig-5. Proliferation of fibrous tissue
All these can ultimately lead to vitreous hemorrhage, traction
detachment of retina and finally blindness.
4) DIABETIC MACULAR OEDEMA
It is defined as edema manifesting as thickening encircling within
two disc diameters from the macular centre. If quite close to the centre of
macula, it is known as clinically significant macular edema (CSME).
Fig-6. Diabetic Maculopathy
5) POST PHOTOCOAGULATION STATUS
This type is one where there are multiple small scars in the retinal
periphery as a result of photocoagulation.
Fig-7. Retinal view after photocoagulation.
6) UNCLASSIFIABLE
This type of retinopathy is ungradeable, probably because of
difficulty in visualization because of opacities like cataract.
DIAGNOSIS AND MANAGEMENT
Diagnosis depends on the appearance and evolution of DR and on
the  factors that influence this.
The retina is usually studied by
? Ophthalmoscopy
? Slit lamp Biomicroscopy
? Fundus photography (gold standard)
? Digital colour photography
? Optical coherence tomography (OCT).
Management strategies are Laser photocoagulation and vitrectomy
.  Intravitreal  injections  of  steroids  may  be  useful  in  severe  CSME.  Few
antiproliferative agents are also under trial.
DIABETIC LV DYSFUNCTION
Diabetic cardiomyopathy is a syndrome continuum that involves
the myocardium and resulting in a number of derangements in structure
ultimately leading to hypertrophy of left ventricle and abnormalities of
systole  or  diastole  or  both.   It  is  already  known  that  diabetics  are  at
increased risk of high BP and coronary artery disease (32); however
diabetic cardiomyopathy can occur without the presence of these other
factors.
Thus by definition, it is a “unique entity featured by abnormal
myocardial  function  or  structure  in  the  lack  of  CAD  /  hypertension  /
valvular heart disease.”
FACTORS CONTRIBUTING:
AGE
It is a vital variable determining cardiovascular disease, whose
incidence is appreciably higher in patients above the age of 60 years (26).
SEX
Diabetes is probably the only condition in which women have heart
diseases rates equal to men. In the Rancho Bernardo Study diabetic
women had ischemic heart disease mortality rates higher than men. This
could be because of women’s lipoprotein profile being altered when
associated with diabetes. Still, though diabetes accelerates the virtual risk
in females, the total danger for cardiac mortality is undoubtedly larger in
males than females (25).
HYPERGLYCEMIA, DURATION OF DIABETES AND
GLYCEMIC CONTROL
Hyperglycemia is a stronger interpreter of microvascular
complication when compared to macrovasculart disease in diabetics.
Unoptimally treated hyperglycemia is a potential risk attribute (24, 49).
The associations between glycemic control and diastolic filling were
found positively in studies of Hiramatsu (28), Vanninen (29) and Beljic et
al (30).  Holzmann studied the association of HbA1C and heart disease in
individuals with Non insulin dependent diabetes (31).
HYPERTENSION
Elevated blood pressure levels have been noticed in diabetics quite
consistently independent of age, BMI and renal disease and its prevalence
accelerates with duration of diabetes and is greatly accentuated in the
presence of diabetic nephropathy (60) .The mechanisms are not well
understood, but possibly due to insulin and its actions.
DYSLIPIDEMIA
Hypertriglyceridemia, possibly due to more availability of free
fatty  acid  and  glucose  to  the  liver  leads  to  enormous  production  of
VLDL; lipoprotein lipase’s abnormal function results in poor clearance of
both chylomicrons and VLDL. Elevation of total or LDL cholesterol and
decreased HDL cholesterol are other contributors (61-63).
ALCOHOL
Both duration and quantity of alcohol consumption are influencers
of cardiovascular disease. Generally alcoholic diabetics consuming > 90 g
of alcohol a day for five years are at danger. Alcoholic cardiomyopathy, a
nonischemic type of dilated cardiomyopathy is depicted by an increase in
mass of myocardium, ventricle dilatation and thinning of walls.
STROKE
Cerebrovascular accidents are the other major macrovascular
complication of diabetes like cardiovascular disease. Whether they both
are individual contributors to each other is a matter of debate.
 MICROALBUMINURIA
Studies by Sampson et al (20) and Perez et al (21) demonstrated a
decrease in E/A ratio in diabetics according to the presence of
microalbuminuria. Albuminuria is currently   shown in numerous studies
to be a significant independent predictor of cardiovascular disease in
diabetics (64-67). This further leads to the fact that association between
diabetes and cardiovascular disease may have similar determinants with
microvascular complication in the other organs as well.
CARDIOVASCULAR AUTONOMIC NEUROPATHY
It is manifested as tachycardia at rest, intolerance of exercise,
perioperative cardiovascular instability, orthostatic hypotension, silent MI
and the Cardiac Denervation Syndrome, manifesting as abnormalities in
LV systolic and notably diastolic function (68). This was demonstrated in
studies of Monteagudo et al (22) and Sacre et al (69).
PERIPHERAL VASCULAR DISEASE
Patients might have an extraordinarily increased risk for cardiac
events, particularly large-vessel disease (70). Its prognosis as correlated
with the severity is calculated by the Ankle brachial index (71).
THYROID
Abnormalities in cardiac performance can occur in both patients
with hyperthyroidism state or hypothyroidism parallel with diabetes.
Contractility of the myocardium is augmented in the hyperthyroid and
decreased in hypothyroidism. This is probably because of alterations in
the proteins causing cardiac contraction. It is due to cumulative effects of
the thyroid hormone per se and also changes in the cardiac
responsiveness to sympathetic and hemodynamic alterations.
OTHER ENDOCRINE DISORDERS like adrenal cortical
insufficiency and acromegaly also cause cardiovascular disease by a
variety of causes.
CUMULATIVE RISK FACTORS
Type 2 diabetics usually have manifold heart disease risk factors,
in the likes of hypertension, altered lipid profile, absence of activity,
smoking and central obesity. Additive risk variables significantly
multiply the all over cardiac risk (27).
OTHER FACTORS
The Insulin Resistance Syndrome (72), chronic inflammatory state,
disturbed function of endothelium (73) and thrombotic state are all said to
contribute to diabetic cardiac disease.
PATHOPHYSIOLOGY
The earliest finding is diastolic dysfunction, i.e., dysfunction of
ventricular relaxation and passive filling.  In cardiomyopathy with
systolic failure, collagen deposition in myocardium (74) and AGE (75)
are the chief pathological processes leading to loss of elasticity of the
myocardium, whereas augmented cardiomyocyte resting tension (76)
could be the chief cause in diastolic failure.
Four main causes are responsible for this:
? Microangiopathy and thereby dysfunction of endothelium (73).
? Autonomic neuropathy.
? Alterations in metabolism such as altered glucose usage and
augmented oxidation of  fatty acid, production and accretion of free
radicals.(77)
? Changes in ion dynamics, particularly calcium (78), decreased
function of Na+-Ca2+ swap pump systems, decrease in a Na+-
K+ ATPase subunit expression and other potassium current
disturbances.
STRUCTURAL CHANGES
Changes in the structure are reflected by hypertrophy of the
ventricle. LVH is usually stated as the upper five percentage of the
distribution of LV mass in the general population and this could be
assessed by ECG criteria or ECHO.
FUNCTIONAL ALTERATIONS
DYSFUNCTION OF SYSTOLE
It is an impaired ability of the heart to drive out blood; the chief
feature of systolic dysfunction is a decreased LV ejection fraction. The
various determinants found in the echo evaluation are:
1. Ejection fraction calculation by LV dimensional technique –
Simpson’s method or M- mode Echocardiography.
2. dP/dT of the regurgitant jet across the mitrals.
3. Doppler calculation of stroke volume and thence the total output.
DIASTOLIC DYSFUNCTION
Diastolic phase of the heart has 4 subphases namely (79)
? Relaxation-isovolumic phase,
? Premature filling,
? Diastasis,
? Contraction of atrium.
FACTORS INFLUENCING LV FILLING
? Relaxation of myocardium
? Contraction of atria
? Viscoelastic properties
? Pericardial influences
? Inter Ventricular interaction
? Turgor of Coronary arteries
? Pre- load and after load.
? Conduction pathway.
Their ultimate summated effect is over the transmitral gradient of
pressure that decides filling of left ventricle (80). The reason for
dysfunction of diastole may be further divided as a fall of compliance of
the myocardium passively as well as impaired active LV relaxation.
TECHNIQUES TO IDENTIFY DIASTOLIC DYSFUNCTION
Traditionally, cardiac catheterization with measurements of
pressure and volume was the method of choice for evaluating diastolic
function, which could manifest much earlier than systolic dysfunction
(81,  82).  The  relaxation  rate,  rapidity  and  time  span  of  filling  and
stiffness of chambers can be determined but it is an invasive technique
(83).
Of now, DOPPLER ECHOCARDIOGRAPHY (84,85) has
become a vital and easy to do noninvasive diagnostic measure .The
transmitral flow exhibits  a biphasic pattern, with an early crest indicating
swift early diastolic filling (peak E) and a delayed crest indicating
contraction of atria (peak A). Based on this, a structure of grading is
designed.
Three classical abnormal filling types typically on the basis of E/A
ratio have been put forth (86).
1. The 1st type called “delayed relaxation”, leads to a reversal of E/A ratio
(E/A ?1) where relaxation is hampered.
2.  The  2nd type, depicting dysfunction of relaxation and compliance,
known  as  pseudonormalization,  due  to  normalized  E/A  ratio  (E/A
equaling 1). This is because left atrial pressure increases to compensate
for slow relaxation.
3. The third type, known as “restrictive filling”, seen in extreme fall in
ventricular compliance leading to a high E/A ratio (above 2).
TISSUE DOPPLER ECHOCARDIOGRAPHY
The advantage is that it is not influenced by changes in pre-load. It
also identifies cardiac contraction both longitudinally and
circumferentially, enabling it to detect even subtle dysfunction.
INTRAVENOUS CONTRAST ECHOCARDIOGRAPHY
It provides an assessment of integrity of the microvasculature and
thus perfusion using the resonance of microbubble contrast agents.
3D ECHO
It  does  not  use  arithmetic  predictions  to  quantify  volumes  on  the
contrary to 2D. It is of particular usefulness in ventricles with unusual
shapes and regional wall motion abnormalities.
COMPUTED TOMOGRAPHY
The coronary artery calcification score can be calculated using but
its significance with diabetic cardiomyopathy is not known.
MRI (MAGNETIC RESONANCE IMAGING)
MPI (myocardial perfusion imaging) and thence assess MFR
(myocardial flow reserve) can be assessed using MRI.
SPECT (SINGLE PHOTON EMISSION CT)
It is an on-par system to nuclear cardiology for the identification of
vessel abnormalities and myocardial perfusion.
MANAGEMENT
Diabetic cardiomyopathy requires multipronged treatment
approach as the causes are multifactorial. It includes optimal glycemic
control by way of diet modification, OHAs, insulin and treatment of
failure symptoms. Angiotensin converting enzyme (ACE) inhibitors and
beta blockers may be particularly useful in influencing ventricular
remodeling.
ASSOCIATION BETWEEN DIABETIC RETINOPATHY AND
LEFT VENTRICULAR DYSFUNCTION
Researchers have shown that DR could be linked with overt or
subclinical coronary disease as evidenced by Hallman, Aguilar, Piller LB,
et al (87).  Studies have made known that diabetics with retinopathy can
have perfusion problems in myocardium, inferior coronary reserve, less
coronary collaterals, increased calcification and extensive stenosis of
arteries. It puts highlight on the fact that these microvascular and
macrovascular complications might have common pathways and that
cardiac disease might have a microvascular etiology other than the
traditionally proposed macrovascular component.
“COMMON SOIL” HYPOTHESIS OF DIABETIC
COMPLICATIONS
Experimental data have put forth that complications of micro and
macrovasculature have similar pathophysiologies such as endothelial
dysfunction function, inflammatory state, angiogenesis, programmed cell
death and coagulation abnormalities.
Brownlee in his studies (88) has demonstrated that the sole basis
for complications could be over zealous formation of superoxide radicals
induced by hyperglycemia which in turn activates 4 gateways:
? polyol pathway
? hexosamine gateway
? protein kinase C (PKC) gateway
? AGE
Also insulin resistance produced by FFA causes augmented
superoxide formation thus activating inflammatory state leading to
impaired endothelial function.
ADVANCED GLYCATION END PRODUCTS
Chemical reactions among sugars and proteins yield advanced
glycation end products. These have multiple effects like alteration of
endothelium and collagen thickening. (89)
Specifically in retinopathy, it causes:
? apoptosis of pericytes in retina
? increased formation of VEGF,IGF-1,bFGF and HGF
?  increase pathologic neovascularization
? Augment inflammation in vasculature.
Ultimately it causes endotheleial disturbance,thrombus formation
and ischemia in retina. Angiogenesis, haemorrhage and finally fibrosis
causes tractional retinal detachment and visual loss ensues. (90).
CVD PATHOGENESIS IN DIABETES
It has multifactorial causations; though, the common ground of
injury is the endothelium. Diabetes first inhibits NO and blocks
vasodilatation .Hyperglycemia itself inhibits the enzyme eNOS, augments
the formation of reactive oxygen species tracking to furthermore
inhibition  of  eNOS  as  a  vicious  cycle  (91).  Also  the  NO  induced  tissue
plasminogen activator formation is impaired.Insulin resistance adds to
this and also leads to increased FFA release from adipose and induces the
ProteinKinase C pathway, which can again disrupt nitric oxide synthase
activity through generation of reactive oxygen species. (72).
There is also an overproduction of vasoconstrictor substances such
as endothelin 1,  which mediates its  effects  either  directly or  through the
renin angiotensin system.
Another common mechanism is a state of inflammation. These
cells enter damaged endothelium and drift further deeper, imbibing LDL
in oxidized state and thus resulting in foam cells,  which are the basis  of
atherosclerosis. (62)
In conclusion, there are verifiable associations of DR with
amplified risk of cardiovascular disease, independent of the established
risk variables. More so, it may be that microvascular complications of
diabetes manifest earlier than macrovascular complications. Therefore the
benefits of treatments that reduce the risk for microvascular disease will
ultimately reduce macrovascular disease as well. Thus patients having
retinopathy concurrent with diabetes should undergo a thorough
assessment of cardiac status periodically.
AIMS AND OBJECTIVES
1) To compare LV function by ECHO in Type 2 Diabetes mellitus
patients with and without retinopathy.
2) To look for possible association between severity of DR and
severity of cardiac dysfunction by ECHO, independent of possible
confounding factors.
MATERIALS AND METHODOLOGY
Study Place :  Department of General Medicine,
   Government Stanley Medical College &
   Hospital.
Study period :  March 2012 to October 2012.
Study Design :  Nested Case Control Study.
Sample size : 100 subjects.
INCLUSION CRITERIA:
Type 2 Diabetes mellitus patients attending Government Stanley
Medical College and Hospital as Op/Ip.
EXCLUSION CRITERIA:
1) Previous history of cardiovascular disease.
2) Previous ocular diseases.
3) Concurrent medication with drugs altering cardiac dynamics.
Detailed history and thorough examination of the type 2 diabetes
mellitus  patients  who  were  enrolled  in  the  study  were  done.   Fundus
examination, retinopathy assessment and grading were done. ECHO was
done and left ventricular function assessed.  LV dysfunction in the study
subjects in the presence or absence of retinopathy was compared.
The following data were collected from the patients.
Name :
Op/ Ip no :
Age :
Sex :
DIABETIC HISTORY: Age of onset, Duration.
CO MORBIDITIES: Hypertension, CVA, Nephropathy, Neuropathy,
Diabetic foot, Peripheral vascular disease, Thyroid abnormalities, other
endocrine abnormalities.
PERSONAL HISTORY: Smoking , Alcohol .
Blood pressure: reading of 140/90 mmHg was taken as
hypertension.
Clinical assessment for CVA, peripheral vascular disease and
neuropathy.
INVESTIGATIONS
? Blood sugar levels-fasting and post prandial
? HbA1C levels : levels>6.5% was taken as poor glycemic control.
? Renal function tests: Urea, Creatinine
? Urine-Albumin,Sugar,Deposits
? 24 hr urine proteinuria
? USG abdomen
? Fasting  lipid profile: dyslipidemia was defined as a value of total
cholesterol>200 mg/dl, TGL>150 mg/dl, HDL <40 mg/dl( men)
and <50 mg/dl (women)
? Fasting thyroid function tests
? ECG
? Echocardiogram: 2D ECHO - to determine ejection fraction,mitral
regurgitant jet volume calculation,E/A ratio calculation.
? Fundus examination: Done by ophthalmoscopy and subsequently
slit lamp examination and fundus photography and graded as
O - Normal
1 - Background non proliferative
2 - Preproliferative
3 - Proliferative
4 - Maculopathy
5 – Post photocoagulation status
6 - Unclassifiable.
STATISTICAL ANALYSIS
Data were collected in a preformed proforma. Statistical analysis
was done using SPSS version 11.0 for Windows. Categorical data were
expressed as absolute counts and percentages. Continuous data were
expressed as mean and standard deviation.
For the variables in qualitative form, Chi square and Fisher’s exact
test was used in univariate analysis and further multivariate logistic
regression was utilised to observe the association between the study
variables and outcome. A p value of less than 0.05 was considered
significant.
RESULTS AND OBSERVATIONS
A total of 100 subjects were included in the study. There were a
total of 47 male patients and 53 female patients. A total of 42 subjects
were aged above 60 years, the median age was 55.50 years with 95% C.I.
being 53.2 to 57.5 years. Sixty five patients (65%) had a duration of
diabetes for more than five years. Fifty eight patients (58%) among the
study subjects had poor glycemic control.
Twenty four patients had comorbid hypertension, 39 patients had
additional dyslipidemia. There were in total 18 subjects who gave history
of smoking and 13 subjects with history of alcoholism.
Two of the study subjects had cerebrovascular accident, 3 had
diabetic foot, 1 had peripheral vascular disease, 10 patients had diabetic
nephropathy. In addition, two patients had co-existing thyroid disorders.
The incidence of diabetic retinopathy was 38% among the study
population, and a total of 46% of study subjects had evidence of cardiac
dysfunction. Twenty patients had systolic dysfunction, 43 patients had
diastolic dysfunction and 17 patients had both. Thirty four of the study
subjects with LV dysfunction (LVD) had coexistent diabetic retinopathy
(74%).
Table-1. Distribution of retinopathy among study population
TOTAL RETINOPATHY 38
BACKGROUND 23
PRE-PROLIFERATIVE 8
PROLIFERATIVE 3
MACULOPATHY 4
Table-2. Distribution of cardiac dysfunction among study population
TOTAL
LVD
SD
DD
GRADE 1
DD
GRADE 2
DD
GRADE 3
BOTH
SD AND
DD
46 20 33 7 3 17
A total of 26 patients who were more than 60 years had LV
dysfunction in some form and the odds of patient >60 years to develop
LV dysfunction was 3.0 compared to those less than 60 years, p value
being <0.01. Forty patients among those with cardiac dysfunction (87%)
had duration of diabetes more than five years and the odds of developing
LV dysfunction for those with duration of diabetes more than five years
was 7.73 compared to those with duration of diabetes less than five years,
p value being significant (p<0.05).
Table-3. Association of various factors with LVD in the study subjects
Factor
LVD
Present
n=46
LVD
Absent
n=54
Odds
Ratio
95% C.I. p value
Age>60 years 26 16 3.09 1.353-7.047 0.007
Male sex 23 25 1.160 0.528-2.550 0.712
DM Duration
> 5 years
40 25 7.73 2.813-21.257 0.000
Poor
glycemic
control
29 29 1.471 0.659-3.282 0.346
Hypertension 13 11 1.540 0.612-3.873 0.357
Dyslipidemia 16 23 0.719 0.319-1.619 0.425
Smoking 7 11 0.702 0.247-1.989 0.504
Alcoholism 7 6 1.436 0.446-4.624 0.543
Nephropathy 6 4 1.875 0.427-8.610 0.349
It is seen that age > 60 years and duration of diabetes more than 5
years were both significantly associated with LV dysfunction in the study
subjects. Other factors such as gender, glycemic control, hypertension,
dyslipidemia, smoking did not have any statistically significant
association with the presence of cardiac dysfunction among the study
subjects.
Fig-8. Age distribution of patients with LV dysfunction
Among the patients with cardiac dysfunction, 26 patients (56.5%)
were more than 60 years compared to 16 patients (29.6%) among those
without cardiac dysfunction, which was statistically significant (p<0.01).
There were 23 males (47.9%) and 23 females (44.2%), which was not
statistically significant (p=0.712).
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Fig-9. Diabetes duration in patients with cardiac dysfunction
Among those with diabetes duration for more than five years, 40
patients(61.5%) had LV dysfunction compared to 25 patients(38.5%) who
had no cardiac dysfunction, which was statistically significant (p<0.05).
The odds of patients who are diabetic for more than 5 years are 7.73 to
develop cardiac dysfunction compared to those who are diabetic for less
than 5 years.
0
5
10
15
20
25
30
35
40
Duration >5years Duration<5years
40
6
25
29
LVD present
LVD absent
Fig-10. Glycemic control in patients with cardiac dysfunction
Out of 46 patients with LV dysfunction (LVD) 29 (63%) had poor
glycemic control, compared to 17 (37%) with good glycemic control. The
association was not statistically significant (p=0.34). Other factors such
as smoking, alcoholism also did not have a significant association with
cardiac dysfunction.
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Fig-11. Hypertension in patients with LV dysfunction
The presence of hypertension did not have statistically significant
association with the development of LV dysfunction (p=0.357).
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Fig-12. Dyslipidemia in patients with LV dysfunction
The presence of dyslipidemia did not have statistically significant
association with the development of LV dysfunction (p=0.425).
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Table-4. Multivariate logistic regression for variables associated with LV
dysfunction
Variable
Standard
Error
Adjusted
Odds Ratio
95% C.I P Value
Diabetic
Retinopathy
present
0.72 40.08
9.84-
163.25
p<0.001
Diabetes
Mellitus
Duration >5
years
0.75 7.41 1.70-32.3 p<0.01
Multivariate analysis revealed that presence of diabetic retinopathy
and duration of diabetes more than 5 years were independently associated
with LV dysfunction in the study subjects.
Fig-13. Diabetes duration in patients with retinopathy
A total of 31 patients (91.2%) who had duration of diabetes more
than 5 years also had retinopathy, compared to a total of 7 patients (25%)
with disease duration of less than 5 years who developed retinopathy as a
complication.
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Fig-14. Nephropathy in patients with retinopathy
Among  the  study  subjects,  a  total  of  10  patients  had  evidence  of
nephropathy, all of whom also had concomitant retinopathy.
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Table - 5. Association of various factors with retinopathy in the study
subjects
Factor
Diabetic
retinopathy
present
n=38
Diabetic
retinopathy
absent
n=62
Odds
ratio
95% C.I.
p
value
Age > 60
years
19 23 1.69 0.69-4.17 0.20
DM duration
> 5 yrs
31 34 3.64
1.28-
10.72
0.007
Poor glycemic
control
22 36 0.99 0.40-2.44 0.98
Hypertension 7 17 0.59 0.19-1.77 0.30
Dyslipidemia 17 22 1.47 0.59-3.64 0.35
Nephropathy 10 0 0.00
Univariate analysis of various factors associated with retinopathy
revealed that duration of diabetes more than 5 years and presence of
diabetic nephropathy had statistically significant association with the
development of retinopathy.
Other factors such as age, gender, glycemic control, hypertension,
dyslipidemia, smoking, alcoholism did not have statistically significant
association with presence of diabetic retinopathy.
Fig-15.  LV dysfunction in patients with diabetic retinopathy
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Fig-16.  LV Dysfunction in patients without diabetic retinopathy
  It was observed that 89.5% of patients with diabetic retinopathy
had LV dysfunction compared to 19.4% patients among those without
diabetic retinopathy, and the p value was significant (p<0.001) as
evaluated by Fisher’s exact test.
12
50
Present
Absent
Fig-17. Scatter diagram showing correlation of grades of Retinopathy and
Diastolic dysfunction
From  the  above  scatter  plot,  it  is  evident  that   a  strong  positive
correlation exists between the grades of Retinopathy and grades of
Diastolic Dysfunction (DD) and  is found to  be significant (Correlation
co-efficient =0.897; C.I.= 0.85-0.92, p<0.0001).
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Fig -18. Age distribution among patients with cardiac dysfunction with
and without retinopathy
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Fig-19. Sex distribution among patients with cardiac dysfunction with
and without  retinopathy
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Fig-20. Duration of diabetes mellitus among the patients with cardiac
dysfunction
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Fig-21. Glycemic control among patients with cardiac dysfunction
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Fig-22. Dyslipidemia among the study subjects with cardiac dysfunction
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There was no statistically significant difference between the two
groups with respect to the presence or absence of dyslipidemia.
Table-6. Comparison between patients with and without retinopathy who
developed LV dysfunction
Variable
No. of
patients
with
retinopathy
No. of
patients
without
retinopathy
P
value
Odds
ratio
95% C.I.
Age > 60 18/34 7/12 0.747 0.804 0.174-3.643
Diabetes
duration > 5
years
28/34 12/12 0.119 0 0-2.639
Poor
glycemic
control
20/34 9/12 0.318 0.476 0.083-2.470
Hypertension 7/34 6/12 0.05 0.259 0.005-1.287
Dyslipidemia 16/34 3/12 0.182 2.667 0.518-15.203
Factors such as age, gender, duration of diabetes, glycemic control,
hypertension, dyslipidemia did not differ significantly between   those
with and without retinopathy who developed cardiac dysfunction.
DISCUSSION
A  total  of  100  diabetic  patients  were  included  in  the  study,  and
cardiac function was assessed by 2D and Colour Doppler
echocardiography. The study subjects included patients with type 2
diabetes mellitus. Previous studies which analysed cardiac function in
diabetic subjects included type 1 diabetes as in studies by Sampson et al
(82),  Perez  et  al  (39),  while  similar  study  was  done  in  type  2  diabetes
patients by Annonu et al (41).
A total of 46 patients had LV dysfunction (LVD), among which 20
had systolic dysfunction, 33 had diastolic dysfunction and 17 had both
systolic and diastolic dysfunction. Historically, cardiac dysfunction was
assessed by cardiac catheterization (92) and later non-invasive methods
were employed which included irregular time intervals by using
phonocardiograms, assessment of ventricular filling by standard ECHO
(93), as well as Doppler ECHO.
Diastolic dysfunction was more prevalent than systolic dysfunction
which  was  similar  to  the  observations  by  Raev  et  al  (94).  The  subjects
included in the study by Raev et al included Type 1 Diabetes mellitus
patients.  In  the  study  by  Cosson  et  al,  69%  of  the  subjects  had  cardiac
dysfunction (95), compared to our study where 46% had cardiac
dysfunction. This could be explained by the technical limitations in
echocardiography.
There were totally 38 patients with retinopathy and the distribution
of retinopathy was as follows: 23 (60.5%) had background retinopathy, 8
(21%) had pre-proliferative retinopathy, 3 (8%) had proliferative
retinopathy and 4 (10.5%) had diabetic maculopathy. There were no
significant differences between age, sex, dyslipidemia, glycemic control,
dyslipidemia and hypertension.
However, significant association was found between presence of
diabetic nephropathy and duration of diabetes more than 5 years. A study
by Aguilar et al revealed noteworthy dissimilarities in sex, smoking and
lipid profile between the two groups. Also more severe grade of
retinopathy was linked with hypertension, prolonged diabetes duration
and albuminuria in that study (87).
A more severe grade of retinopathy was coupled with higher grades
of cardiac dysfunction which was similar to the observations made by
Aguilar et al (87). However, studies by Airaksinen et al (42) and Uusitupa
et al (43) did not find any significant association with cardiac dysfunction
and presence or absence of retinopathy.
Multivariate analysis revealed that presence of retinopathy and
duration of diabetes more than five years had significant association with
the development of LV dysfunction in the study subjects. The results are
similar  to the study done by Virendra et  al,  where diabetic  patients  with
retinopathy had higher incidence of LV diastolic dysfunction and it
correlated with the duration of diabetes mellitus in the study subjects
(96).
CONCLUSIONS
Type 2 Diabetes mellitus patients with diabetic retinopathy had
significant association with impaired LV function detected by
echocardiography in comparison to those without retinopathy. The
severity of retinopathy in these patients correlated with grade of diastolic
dysfunction.
Diabetic patients who are detected with retinopathy should also be
assessed for asymptomatic cardiac involvement. However, there must be
studies with a larger sample size and follow up period to know the natural
history of cardiac involvement in patients with type 2 diabetes mellitus
and trials to study the benefit for cardiac screening in such individuals,
before strong recommendations are made.
ANNEXURES
PROFORMA
PATIENT DETAILS
? Name:
? OP/ Ip no:
? Age:
? Sex:
? Occupation:
? Address:
? DIABETIC HISTORY
Age of onset:
Duration:
? Mode of treatment:
 1. Oral hypoglycemic agents
 2. Insulin
? COMORBIDITIES:
HT/CVA/Nephropathy/Neuropathy/DF/PVD/Thyroid/Other
Endocrine Abnormalities
? PERSONAL  HISTORY : Diet ,Smoking ,Alcohol
? FAMILY HISTORY
EXAMINATION
? General  examination
? BMI
? BP
? Cardiovascular system examination
? Respiratory  system examination
? Per abdominal examination
? Nervous system examination: Higher motor functions, Cranial
nerves, Motor  system, Sensory system.
? FUNDUS
INVESTIGATIONS
? Blood sugar-Fasting blood sugar, Post prandial blood sugar.
? HbA1c levels.
? Renal function test-Urea, Creatinine.
? Urine-Albumin, Sugar, Deposits.
? 24 hr urine proteinuria
? Fasting   lipid profile
? Fasting Thyroid function tests
? USG abdomen
? ECG
? Echocardiogram
ABBREVIATIONS
? DM-diabetes mellitus
? DM DUR-diabetes mellitus duration
? POOR GC-poor glycemic control
? DR-diabetic retinopathy
? LV-left ventricle
? LVD-left ventricular dysfunction
? LVH-left ventricular hypertrophy
? CVD-cardiovascular disease
? CAD-coronary artery disease
? CVA-cerebrovascular accident
? ECG-electrocardiogram
? ECHO-echocardiogram
? HT-hypertension
? DL-dyslipidemia
? SMO-smoking
? ALC-alcohol
? PVD-peripheral vascular disease
? DF-diabetic foot
? THY-thyroid
? ENDO-endocrine disorders
? NEP-nephropathy
? NEU-neuropathy
? G.RE-grading of retinopathy
? SD-systolic dysfunction
? DD-diastolic dysfunction
? RET-retinopathy
? MRI-magnetic resonance imaging
? OHA-oral hypoglycemic agents
? GDM-gestational diabetes mellitus
? PCOS-polycystic ovarian syndrome
? DKA-diabetic ketoacidosis
? BMI-body mass index
? BP-blood pressure
? IRMA-intraretinal microvascular abnormalities
? NVD-new vessels on the disc
? NVE-new vessels elsewhere
? WESDR- Wisconsin Epidemiologic Study of Diabetic Retinopathy
? CURES-chennai urban rural epidemiological study
? DCCT- Diabetes Control and Complications Trial
? UKPDS-united kingdom prospective Diabetes study
? VEGF-vascular endothelial growth factor
? GH-growth hormone
? TGF-transforming growth factor
? CSME-clinically significant macular edema
? AGE-advanced glycation end products.
? MI-myocardial infarction
? FFA-free fatty acid
? IGF-insulin like growth factor
? HGF-hepatocyte growth factor
? FGF-fibroblast growth factor
? NO-nitric oxide
? eNOS-endothelial nitric oxide synthase.
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MASTER CHART
S No NAME IP/OP NO AGE SEX DM DUR POORGC HT DL SMO ALC CVA PVD DF THY ENDO NEP NEU
G.
RET SD DD RET LVD
1 ulaganathan 38162 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
2 kumar 38065 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1
3 krishnaveni 3901 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
4 selvan 37146 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1
5 revathy 4397 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 3 1 1 1 1
6 arumugam 35294 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1
7 jayaraman 36289 1 1 1 0 1 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0
8 devika 30832 0 0 1 0 0 1 0 0 0 0 0 0 0 1 0 4 1 2 1 1
9 mary 43835 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
10 aruldoss 35144 0 1 1 1 0 0 0 0 0 0 0 0 0 1 0 0 1 1 0 1
11 rathnamal 81479 1 0 1 1 1 0 0 0 0 0 0 0 0 0 0 4 1 2 1 1
12 prem kumar 31644 0 1 1 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
13 kamala 20224 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
14 periyasamy 23560 1 1 1 1 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 1
15 latha 43845 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
16 sharada 30284 1 0 1 0 0 1 0 0 0 0 0 0 0 0 0 1 0 1 1 1
17 jothi 43096 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1
18 musthafa 32640 1 1 1 0 1 1 0 0 0 0 0 0 0 1 0 0 1 1 0 1
19 kala 53916 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
20 sujatha 30159 0 0 1 1 0 1 0 0 0 0 0 0 0 1 0 3 1 1 1 1
21 ganesan 5277 0 1 0 0 1 1 0 0 0 0 0 0 0 0 0 1 0 1 1 1
22 maniyamal 42773 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1
S No NAME IP/OP NO AGE SEX DM DUR POORGC HT DL SMO ALC CVA PVD DF THY ENDO NEP NEU
G.
RET SD DD RET LVD
23 kalyani 29969 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 2 0 1 1 1
24 jaya 42068 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1
25 mani 40752 1 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0
26 lakshmi 42069 1 0 1 1 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 1
27 iqbal 31698 1 1 1 1 0 0 0 1 0 0 0 0 0 1 0 2 0 2 1 1
28 rajeshwari 42054 1 0 1 1 0 1 0 0 0 0 0 0 0 1 0 1 1 1 1 1
29 kannan 30734 1 1 1 1 0 1 0 0 0 0 0 0 0 0 0 1 0 1 1 1
30 edwin 30719 0 1 1 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
31 vasantha 41995 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
32 elumalai 27574 1 1 1 0 0 0 1 1 0 0 1 0 0 0 0 1 0 1 1 1
33 rani 41971 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
34 krishnan 27548 0 1 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
35 komala 41058 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1
36 samuel 25575 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
37 elizabeth 40045 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
38 pitchumani 32642 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 2 0 1 1 1
39 sathya 39237 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 1 0 1 1 1
40 ibrahim 43398 0 1 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0
41 mahalingamal 48615 0 0 1 0 0 1 1 0 0 0 0 0 0 0 0 4 1 3 1 1
42 thilagam 39101 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 1 0
43 minnala 263454 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0
44 kannan 41942 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0
45 kaliamal 37142 1 0 1 1 0 1 0 1 0 0 0 0 0 0 0 2 1 1 1 1
46 amaravathy 37176 1 0 0 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0
47 kaliyappan 42010 0 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 1 0 1
S No NAME IP/OP NO AGE SEX DM DUR POORGC HT DL SMO ALC CVA PVD DF THY ENDO NEP NEU
G.
RET SD DD RET LVD
48 francis 42722 1 1 1 1 1 0 0 1 0 0 0 0 0 1 0 0 1 0 0 1
49 govindaraj 42766 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
50 pushpa 24644 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
51 thanayan 42756 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
52 shanmugam 39080 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
53 ramalingam 40058 1 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
54 alangaram 36290 1 0 1 1 0 1 0 0 0 0 0 0 0 0 0 1 0 1 1 1
55 rajan 41005 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
56 mannangati 41067 1 1 1 1 1 0 0 0 0 0 0 0 0 1 0 2 0 1 1 1
57 muniyamal 39021 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
58 baskaran 43026 0 1 0 1 0 1 1 0 0 0 0 1 1 0 0 2 0 2 1 1
59 viji 42316 0 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
60 rathiamal 42737 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
61 mathialagan 41055 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 2 1 2 1 1
62 mohanavalli 36253 1 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
63 muthulakshmi 36223 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
64 moorthy 40851 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1
65 devendran 40285 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
66 vijayalakshmi 36241 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
67 mubarakbasha 40281 0 1 0 1 0 1 0 0 0 0 0 0 0 0 0 1 0 1 1 1
68 mary 35210 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1
69 kamala 35242 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
70 sivakumar 40238 0 1 0 0 0 0 1 1 0 1 1 0 0 0 0 0 0 0 0 0
71 subramani 39367 0 1 1 1 0 1 1 0 0 0 1 0 0 0 0 1 0 1 1 1
72 kanmani 34441 1 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1
S No NAME IP/OP NO AGE SEX DM DUR POORGC HT DL SMO ALC CVA PVD DF THY ENDO NEP NEU
G.
RET SD DD RET LVD
73 govindammal 34436 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
74 selvaraj 39318 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
75 gowri 33558 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 1 0 1 1 1
76 durai 39305 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0
77 perundevi 32636 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1
78 neeladevi 31878 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
79 rathnavel 39277 0 1 1 0 0 1 0 0 0 0 0 0 0 0 0 1 0 1 1 1
80 shakunthala 31625 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
81 jayalakshmi 31746 1 0 1 0 1 0 0 1 1 0 0 0 0 1 0 1 0 1 1 1
82 sekar 39275 0 1 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0
83 veeraraghavan 42335 0 1 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0
84 padma 29248 1 0 1 1 1 1 0 0 0 0 0 0 0 0 0 2 1 2 1 1
85 raniamal 28635 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
86 isrel 38433 0 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
87 devanayaki 26610 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
88 gnanakumari 26593 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
89 amanullah 36497 1 1 0 1 1 0 0 0 0 0 0 0 0 0 0 3 1 3 1 1
90 sathya 25502 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
91 vasantha 24658 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
92 pushpavalli 24644 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
93 moorthy 36534 0 1 1 1 1 0 1 1 0 0 0 0 0 0 0 4 1 3 1 1
94 elumalai 35459 0 1 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0
95 rukmani 23732 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
96 selvambal 21052 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 2 1 1
97 lakshmi 20927 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0
S No NAME IP/OP NO AGE SEX DM DUR POORGC HT DL SMO ALC CVA PVD DF THY ENDO NEP NEU
G.
RET SD DD RET LVD
98 sumathy 20019 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0
99 muthukrishnan 42324 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0
100 chinaiyah 38331 0 1 1 0 0 1 1 1 0 0 0 0 0 0 0 0 1 1 0 1
KEY
1. NAME
2. AGE: below 60-0, Above 60-1
3. SEX: Male -1, Female – 0
4. IP/OP NUMBER
5. DM DUR-diabetes mellitus duration: <5 yrs -0, >5 yrs-1
6. POOR GC- poor glycemic control: Absent – 0,present – 1
7. HT- hypertension: Absent – 0, present – 1
8. DL-dyslipedemia : Absent – 0,present – 1
9. SMO- smoking: Absent– 0, present – 1
10. ALC- alcoholism: Absent – 0, present 1
11. CVA- cerebrovascular accident : Absent – 0, present – 1
12. PVD- peripheral vascular disease: Absent – 0, present – 1
14. DF- diabetic foot : Absent – 0, present – 1
15. THY- thyroid abnormalities: Absent – 0, present – 1
16. ENDO-other endocrine abnormalities: Absent – 0, present – 1
17. NEP-nephropathy: Absent – 0, present – 1
18. NEU-neuropathy: Absent – 0, present – 1
19. G.RET-retinopathy with grading:
Nil -0
Background retinopathy-1
Pre-proliferative -2
Proliferative -3
Maculopathy-4
Photocoagulation-5
Unclassifiable-6
20. SD- systolic dysfunction: absent 0, present 1
21. DD- diastolic dysfunction: Absent – 0, Grade 1 – 1, Grade 2 – 2,
                Grade 3 – 3
22. RET- retinopathy in toto - Absent-0, Present-1
23. LVD-left ventricular dysfunction on the whole: Absent-0, Present-1

